Analysis of Potential Antiretroviral Drug Interactions Among HIV Patients at Puskesmas X, Jambi City, in 2025
DOI:
https://doi.org/10.57235/jetish.v5i2.9130Keywords:
Antiretroviral; Drug Interaction; HIV; Pharmacodynamic; SeverityAbstract
Introduction: Human Immunodeficiency Virus (HIV) infection requires continuous antiretroviral (ARV) therapy involving the use of multiple medications. Such combination therapy may increase the risk of drug interactions, which may potentially affect the efficacy and safety of treatment. Methods: This study employed a non-experimental study design with a descriptive approach and retrospective design. The study data were obtained from secondary data in the form of HIV patient visit records. A total of 72 patients were selected using purposive sampling. Potential drug interactions were identified using Drugs.com, Medscape, and DrugBank, and the data were analyzed descriptively using Microsoft Excel 2021. Results: The majority of patients were in the young adult age group (26–35 years), comprising 27 patients (37.50%), and most were male, with 62 patients (86.11%). The most frequently used ARV regimen was a combination of tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and dolutegravir (DTG), used by 63 patients (87.50%). A total of 18 potential drug interactions were identified, predominantly involving pharmacodynamic mechanisms, accounting for 17 cases (94.44%), while pharmacokinetic interactions accounted for 1 case (5.56%). Regarding severity, 17 cases (94.44%) were classified as moderate and 1 case (5.56%) as major, with no minor interactions identified. Conclusion: Potential ARV drug interactions among HIV patients at Puskesmas X, Jambi City, in 2025 were predominantly pharmacodynamic in mechanism and moderate in severity.
Downloads
References
Auliafendri, N., Sinaga, A. H., & Hasibuan, N. N. (2025). Evaluasi interaksi obat antiretroviral pasien HIV-AIDS rawat inap di Rumah Sakit Umum Imelda Pekerja Indonesia Medan. JIFI (Jurnal Ilmiah Farmasi Imelda), 8(2), 129–136.
Banne, Y., Gurning, S. H., Brata, A., & Jannah, F. (2025). Interaksi obat. Perkumpulan Pendidikan dan Pelatihan Tenaga Kesehatan Progres Ilmiah Kesehatan.
Cachay, E. R. (2024). Human Immunodeficiency Virus (HIV) infection. MSD Manual Professional Edition.
Cachay, E. R., et al. (2024). Human Immunodeficiency Virus (HIV) infection. MSD Manual Professional Version.
Dinas Kesehatan Provinsi Jambi. (2022). Profil kesehatan Provinsi Jambi.
Gandhi, R. T., et al. (2025). Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. PubMed.
Kementerian Kesehatan Republik Indonesia. (2024). Profil kesehatan Indonesia. Kementerian Kesehatan Republik Indonesia.
Kementerian Kesehatan Republik Indonesia. (2025). Berani tes, berani lindungi diri, Kemenkes targetkan eliminasi HIV dan IMS tahun 2030. Kementerian Kesehatan Republik Indonesia.
Kusuma, R. (2025). Upaya pencegahan HIV pada remaja melalui edukasi di Posrem Eirin Kota Jambi. 7(1), 15–24.
Nabila, N. A., Karim, M. A., & Akhmad, A. D. (2025). Characteristics and evaluation of potential drug interactions among HIV/AIDS outpatients: A retrospective study at primary health center in a North Lampung Regency, Indonesia. Pharmacy Reports, 5(1), 102.
Permatasari, J., Budi, M., & Meirista, I. (2020). Profil sosiodemografi dan terapi antiretroviral pada pasien HIV/AIDS rawat jalan RSUD Raden Mattaher Jambi periode tahun 2017–2018. As-Syifaa Jurnal Farmasi, 12(2), 84–90.
Permatasari, J., Budi, M., & Meirista, I. (2020). Profil sosiodemografi dan terapi antiretroviral pada pasien HIV/AIDS rawat jalan RSUD H. Abdul Manap Jambi. Journal Pharmasci (Journal of Pharmacy and Science), 6(2), 75–79.
Permatasari, J., Sutrisno, D., & Herdiyanti, R. (2020). Studi interaksi obat antiretroviral pada pasien HIV/AIDS rawat jalan di RSUD Raden Mattaher Jambi. Farmasains: Jurnal Ilmiah Ilmu Kefarmasian, 7(1), 21–25.
Reviagana, K. P., & Pertiwi, M. R. (2025). Strategi peningkatan kepatuhan pengobatan antiretroviral (SIPATUH ARV) pada orang dengan HIV AIDS (ODHIV), 212–231.
Setiadi, S., et al. (Eds.). (2014). PAPDI: Buku ajar ilmu penyakit dalam (Edisi ke-6). InternaPublishing.
Taborat, M., et al. (2022). Potensi interaksi obat antiretroviral (ARV) pada pasien Human Immunodeficiency Virus (HIV) dan Acquired Immune Deficiency Syndrome (AIDS) di BLUD RSUD Sele Be Solu Kota Sorong tahun 2021. 12(3), 38–43.
World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.
World Health Organization. (2023). HIV WHO 2023. World Health Organization.
World Health Organization. (2025a). Definisi HIV. World Health Organization.
World Health Organization. (2025b). HIV and AIDS. World Health Organization.
World Health Organization. (2025c). HIV terbaru. World Health Organization.
Yayasan KNCV Indonesia. (2023). Pencegahan, pemeriksaan, dan pengobatan HIV untuk kesehatan optimal. Ayo Sehat, Kementerian Kesehatan Republik Indonesia.
Downloads
Published
Issue
Section
Citation Check
License
Copyright (c) 2026 Junita Anggi Rahmawati, Jelly Permatasari, Nurhayati
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors are copyright holders and maintain author rights in accordance with the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) or comparable license. While holding these rights, authors grant the JETISH: Journal of Education Technology Information Social Sciences and Health (publisher of JETISH) a non-exclusive right to the first publication of their articles, including abstracts. This enables us to ensure full copyright protection and to disseminate the article to the widest possible readership in electronic format. Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.
